Comparison of anti-TNF and IL-inhibitors treatments in patients with psoriasis in terms of response to routine laboratory parameter dynamics

Abstract

Background: Biological agent treatments represent a relatively new field and their effects on routine laboratory parameters are not fully known as there has been little research in the area. In our study, we aimed to evaluate the differences between the two main biological treatment groups and their effects on routine laboratory parameters. Methods: Patients were enrolled when they had received treatment for more than six months with biological treatments between January 2013 and April 2020. The available data on routine laboratory parameters were collected by routine blood tests before the treatment, at three months, and at the final evaluation. Results: When the changes in routine laboratory parameters were evaluated by treatment, it was found that the NLR and CRP values decreased statistically significantly in the anti-TNF group compared to the IL inhibitor group. In addition, strong suppression of these inflammation parameters means strong suppression of the immune system response. In addition, AST, ALT, and creatinine values were found to be statistically significantly higher in the anti-TNF group compared to the IL inhibitor group. Conclusions: In our study, anti-TNF treatments are shown to be more effective in reducing inflammation parameters while IL antagonists are safer in terms of biochemical parameters.

The effect of secukinumab treatment on inflammatory parameters in patients with psoriasis: A multicentre restrospective study

“…In the study of An et al, it was found that the NLR value at the 3rd and 6th months of the treatment in patients with psoriasis who received biological agent treatment decreased statistically significantly. However, when four different biological agents (etanercept, adalimumab, infliximab, ustekinumab) were compared, no significant change was found between them in terms of the effect on the NLR value 25 …”

“…An et al found that in patients with psoriasis treated with biological agents, the PLR value at the 3rd and 6th months of treatment was statistically significantly decreased. However, when four different biological agents (etanercept, adalimumab, infliximab and ustekinumab) were compared among themselves, no significant change was found in PLR values 25 …”

“…However, when four different biological agents (etanercept, adalimumab, infliximab and ustekinumab) were compared among themselves, no significant change was found in PLR values. 25 In the study of Ataseven et al, it was reported that PLR value significantly decreased as a result of treatment in patients using anti-TNF (etanercept, adalimumab and infliximab) and IL blockers (ustekinumab, secukinumab). 26 In our study, no statistically significant difference was found between the PLR values before the 4th month of treatment and secukinumab treatment.…”

“…However, when four different biological agents (etanercept, adalimumab, infliximab, ustekinumab) were compared, no significant change was found between them in terms of the effect on the NLR value. 25 Ataseven et al investigated the effect of Anti TNF (etanercept, adalimumab and infliximab) and IL blockers (ustekinumab and secukinumab) on inflammatory parameters in patients with psoriasis. In this study, it was observed that NLR was significantly decreased in patients using biological agents.…”

Evaluation of sex hormone profiles and seminal fluid analysis in psoriatic patients and their correlation with psoriasis severity

“…Ataseven et al [28] reported a significant decrease in proinflammatory indicators in patients with psoriasis treated with anti-TNF inhibitors compared to patients treated with interleukin antagonists. However, it is not yet evident whether the decrease in sperm production in patients with untreated psoriasis is primarily due to the effect of the disease itself on sperm production, or if it arises from the effect of the accompanying inflammatory status with high levels of proinflammatory cytokines that are tumor necrosis factor alpha, interleukin1 alpha and beta.…”